

# Genitourinary Syndrome of Menopause in Breast Cancer Survivors: Current Perspectives on the Role of Laser Therapy

Laura Cucinella<sup>1,2</sup>, Lara Tiranini<sup>1,2</sup>, Chiara Cassani<sup>1,3</sup>, Silvia Martella<sup>4</sup>, Rossella E Nappi<sup>1,2</sup>

<sup>1</sup>Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy; <sup>2</sup>Research Centre for Reproductive Medicine, Gynecological Endocrinology and Menopause, IRCCS San Matteo Foundation, Pavia, Italy; <sup>3</sup>Unit of Obstetrics and Gynecology, IRCCS San Matteo Foundation, Pavia, Italy; <sup>4</sup>Unit of Preventive Gynecology, IRCCS European Institute of Oncology, Milan, Italy

Correspondence: Rossella E Nappi, Research Centre for Reproductive Medicine, Gynecological Endocrinology and Menopause, IRCCS San Matteo Foundation, Piazzale Golgi 2, Pavia, 27100, Italy, Tel +390382501561, Fax +390382516176, Email [nappi@rossellanappi.com](mailto:nappi@rossellanappi.com)

**Abstract:** Genitourinary syndrome of menopause (GSM) is a frequent consequence of iatrogenic menopause or anti-estrogenic adjuvant therapies in breast cancer survivors (BCSs). GSM may profoundly affect sexual health and quality of life, and a multidimensional unique model of care is needed to address the burden of this chronic heterogeneous condition. Severe symptoms may be insufficiently managed with non-hormonal traditional treatments, such as moisturizers and lubricants, recommended as the first-line approach by current guidelines, because concerns exist around the use of vaginal estrogens, particularly in women on aromatase inhibitors (AIs). Vaginal laser therapy has emerged as a promising alternative in women with GSM who are not suitable or do not respond to hormonal management, or are not willing to use pharmacological strategies. We aim to systematically review current evidence about vaginal laser efficacy and safety in BCSs and to highlight gaps in the literature. We analyzed results from 20 studies, including over 700 BCSs treated with either CO<sub>2</sub> or erbium laser, with quite heterogeneous primary outcomes and duration of follow up (4 weeks–24 months). Although evidence for laser efficacy in BCSs comes mostly from single-arm prospective studies, with only one randomized double-blind sham-controlled trial for CO<sub>2</sub> laser and one randomized comparative trial of erbium laser and hyaluronic acid, available data are reassuring in the short term and indicate effectiveness of both CO<sub>2</sub> and erbium lasers on the most common GSM symptoms. However, further studies are mandatory to establish long-term efficacy and safety in menopausal women, including BCSs.

**Keywords:** genitourinary syndrome of menopause, GSM, vaginal laser, breast cancer, vulvovaginal atrophy, VVA

## Introduction

Genitourinary syndrome of menopause (GSM) refers to the multitude of genital, urinary and sexual symptoms developing in women as a consequence of menopause and age-driven anatomical and functional modifications in urogenital tissues.<sup>1</sup> Vaginal dryness, dyspareunia, burning, itching and discomfort are the typical clinical manifestations of vulvovaginal atrophy (VVA), also known as atrophic vaginitis, the genital component of the syndrome.<sup>2</sup> The broader GSM definition includes also urinary symptoms (dysuria, urgency and urinary tract infections) and sexual impact, highlighting a common physio-pathological pattern dictated by a decrease in sex hormones, particularly estrogens, after menopause.<sup>2</sup> Even age-related and/or iatrogenic decline in androgen levels may play a role in the clinical manifestation of GSM.<sup>3</sup>

Breast cancer survivors (BCSs) are particularly vulnerable to develop urogenital symptoms and sexual problems, as a consequence of cancer treatments, which may result in iatrogenic and often premature menopause or may worsen pre-existing conditions related to hypoestrogenism.<sup>4,5</sup> Indeed, GSM is estimated to affect about half of healthy menopausal women,<sup>6</sup> whereas BCSs may display a higher prevalence of urogenital symptoms, reaching up to 70%.<sup>7</sup> Chemotherapy and anti-estrogenic adjuvant therapies [gonadotropin-releasing hormone agonists (GnRH-A), tamoxifen (TMX) and aromatase inhibitors (AIs)] represent the biological insult predisposing to atrophic changes in the urogenital tissues; however, several psycho-social contributors may modulate the presence and severity of urogenital and sexual symptoms

in BCSs,<sup>8</sup> and attitudes toward treatments.<sup>9</sup> Women taking AIs usually report more frequent and severe GSM symptoms compared with those on TMX, possibly because of a more profound state of iatrogenic hypoestrogenism,<sup>10</sup> treatment-emergent endocrine symptoms may be so distressing to lead BCSs to early discontinuation.<sup>11</sup>


Objective vulvovaginal signs are highly present<sup>12</sup> but there is still a lack of early recognition in routine clinical practice that prevents BCSs from receiving adequate care.<sup>13</sup> In general, women presenting with cancer expect their healthcare providers (HCPs) to counsel them about the implications of their condition, including potential effects on sexual function.<sup>14</sup> HCPs do not proactively ask about GSM symptomatology, likely because they do not feel confident in prescribing treatments specific to BCSs,<sup>15</sup> and only half of the oncologists (48%) directly illustrate possible chronic consequences of GSM.<sup>16</sup> That being so, GSM remains an unmet medical need.<sup>17</sup> According to the most recent guidelines and recommendations,<sup>18–22</sup> not all treatment options available for GSM are suitable for BCSs and, therefore, effective management is challenging. Non-hormonal therapies, namely lubricants with sexual activity and regular use of long-acting vaginal moisturizers, are the first-line approach in women with hormone-sensitive breast cancer (BC), whereas data are presently insufficient to confirm safety of some hormonal options [vaginal estrogen or vaginal prasterone or ospemifene, an oral selective estrogen receptor modulator (SERM)] and their use remains a shared clinical decision based on the patient's profile.<sup>18–22</sup>

In the last decade, energy-based treatments have emerged as a possible non-hormonal option to manage GSM symptoms in menopausal women.<sup>23</sup> This minimally invasive technology seemed particularly attractive in BCSs who needed to avoid hormonal exposure.<sup>24</sup> Vaginal laser therapy is the most studied technique to improve vaginal health through controlled heat-associated micro trauma in vaginal tissue, which leads to activation of fibroblasts in the extracellular matrix and promotes collagen and elastic fibers deposition, angiogenesis, and tissue remodeling.<sup>25</sup> Two laser technologies have been tested in women with GSM, the micro ablativ fractional carbon dioxide (CO<sub>2</sub>) laser and non-ablative erbium laser, which differ in wavelength, water absorption and tissue penetration, ultimately determining specific tissue response and remodeling.<sup>26</sup> Promising results obtained in clinical samples of natural menopausal women and in BCSs have driven a strong marketing despite an absence of solid efficacy and safety data in long-term studies.<sup>27</sup> The main factor accelerating the growth of the laser market was the need of both women and HCPs to fill a very relevant gap in GSM treatment deriving from contraindications or low preferences for hormone therapies.<sup>28</sup> However, scientific societies<sup>18–20,29,30</sup> and regulatory agencies, e.g. the Food and Drug Administration (FDA), awaits further efficacy and safety data before officially endorsing energy-based techniques for the management of GSM.<sup>31</sup>

In this article, we systematically reviewed available evidence about vaginal laser efficacy and safety for the treatment of GSM in BCSs. Our aim was to critically discuss data in order to highlight gaps in the literature that should be addressed to eventually define the value of vaginal laser therapy in BCSs among all available therapeutic options.

## Materials and Methods

This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines,<sup>32</sup> as outlined in [Figure 1](#). A comprehensive search was performed in PubMed and Embase prior to March 31, 2023 by two authors (LC and LT). The search was conducted using relevant MeSH terms (“urogenital system”, “menopause”, “vulvovaginitis”, “laser therapy”, “breast neoplasms”), and keywords (“genitourinary syndrome of menopause”, genitourinary, GSM, “vulvovaginal atrophy”, VVA, “laser therapy”, laser, “breast cancer”) related to vaginal laser therapy, GSM and BC (see [Supplementary Appendix for Complete Search Strategy](#)). Reference lists from existing reviews to identify additional relevant studies not identified by the electronic searches were also checked. Studies investigating both CO<sub>2</sub> laser and erbium laser were included. Clinical studies of any design, including interventional and observational, retrospective and prospective, were considered eligible. Publications on peer-review journals, written in English and for which the full text of the article was available were included. Case reports and conference abstracts were excluded from this review because of incomplete data. There were no restrictions on the study time period. Independent review of the full-text manuscripts of the selected studies was performed by two authors (LC and LT) and cases of disagreement were solved by discussion of two other researchers (CC and SM). Two authors (LC and REN) independently extracted and collected the following data: number and characteristics of participants (age, menopause duration and/or age, history of BC and use of adjuvant treatments), study design, type of intervention and therapeutic protocol, duration of follow up, main outcomes, incidence of adverse events, results and author conclusions.



**Figure 1** Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) study selection flow diagram.

## Results

With the search strategy described, we identified 108 eligible articles; after the first screening, 36 articles were retrieved and full text assessed for eligibility. Of them, 16 were excluded (15 conference abstracts and one case report), leading to a total of 20 studies included in the present review.<sup>33–52</sup> All studies were written in English and published between 2016 and 2023. We included three studies reporting different outcomes in the same treated cohort or new information about extended follow-up periods;<sup>41,45,47</sup> we also included two studies from the same research group, reporting outcomes at different stages of patient enrollment.<sup>33,35</sup> The majority of studies included only BCSs, with the exception of 4 retrospective studies, 3 of which also evaluated laser treatment in healthy menopausal women<sup>38,42,46</sup> and one in gynecological cancer survivors.<sup>39</sup> That being so, we calculated that 789 BCSs were included in the studies: 731 of them were treated with vaginal laser (626 with micro ablative CO<sub>2</sub> laser, 105 with non-ablative erbium laser)<sup>33–52</sup> and 21 participants received local hyaluronic acid treatment as control arm.<sup>52</sup>

The type of laser used varied across studies and most of them reported use of the micro ablative CO<sub>2</sub> laser,<sup>33–48</sup> only 4 studies investigated the non-ablative erbium laser.<sup>48–52</sup> Looking at the study design, the majority were single arm prospective studies reporting changes in clinical outcomes (most commonly symptom severity) and appearance of

vaginal epithelium [usually evaluated through the Vaginal Health Index<sup>1</sup> (VHI)] from baseline to follow up; observation times were quite variable, ranging from 4 weeks to a maximum of 24 months. Retrospective studies were also common, while a comparison with local hyaluronic acid was reported only in one randomized trial with erbium laser.<sup>52</sup> Our search identified only one double-blinded randomized sham-controlled trial in the BCSs population.<sup>48</sup> Results reported in individual studies are displayed in [Table 1](#) for fractional micro ablative CO<sub>2</sub> laser and in [Table 2](#) for erbium laser.

## Micro Ablative Fractional CO<sub>2</sub> Laser

Sixteen studies<sup>33–48</sup> evaluated the efficacy and safety of fractional CO<sub>2</sub> laser in 626 BCSs treated for GSM ([Table 1](#)). The micro ablative fractional CO<sub>2</sub> laser was used with rather homogeneous power settings (power 30–40 W, dwell time of 1000 μs, dot spacing of 1000 μm, smart stack parameter of 1–3). Most women underwent 3 sessions of vaginal laser 30–45 days apart, with few exceptions. Outcomes were reported after each treatment and times at follow up were variable after the last treatment, ranging from 4 weeks to 24 months; four studies also reported vulvar treatment with a dedicated probe.<sup>38,41,42,46</sup> Overall, every study observed an improvement in signs and/or symptoms of GSM at short-term follow up, with only few mild adverse events (AEs). Of note, most of the studies were single-arm prospective or retrospective observational studies, with the unique exception of one randomized sham-controlled trial.<sup>48</sup>

In 2016, Pagano et al were the first to publish results of a study on fractional micro ablative CO<sub>2</sub> laser efficacy specifically in a cohort of young BCSs, mostly with iatrogenic menopause and treated with GnRH-A plus TMX.<sup>33</sup> In their retrospective observational study, the authors observed a reduction of visual analogue scale (VAS) for dyspareunia, dryness and itching of 78%, 80% and 75%, respectively, after three vaginal laser sessions; dysuria, vaginal bleeding and vaginal discharges were also frequently resolved.<sup>33</sup> Similar results were replicated and later published by the same group, after expanding the cohort to 82 BCSs; patients were enrolled after failure of non-hormonal treatments (moisturizers or lubricants) and the majority of them were on anti-estrogenic adjuvant therapies (37 women on AIs and 23 women on TMX); in this cohort, neither age nor the type of adjuvant systemic anticancer therapy seemed to affect treatment outcomes.<sup>35</sup>

Three further observational retrospective cohort studies investigated efficacy of fractional micro ablative CO<sub>2</sub> laser in BCSs cohorts as opposed to healthy menopausal women, reporting similar amelioration of vulvovaginal symptoms<sup>42,46</sup> and sexual function by using validated scales.<sup>38,46</sup> By contrast, another retrospective comparison observed a slower improvement of symptoms measured by VAS scores in BCSs in respect with healthy menopausal women, possibly as a consequence of more severe GSM symptoms at baseline.<sup>43</sup> In a large multi-centric retrospective study involving 135 BCSs and 60 women with a history of some other gynecological cancers, Angioli et al reported a decrease in VAS score for vaginal dryness, dyspareunia, pain at the introitus, burning and itching; results were significant in the whole cohort and when the two groups were analyzed separately.<sup>39</sup>

A similar improvement in GSM signs and symptoms was confirmed in prospective studies. Quick et al published three subsequent papers reporting short- and long-term follow up from a single arm prospective study evaluating 67 menopausal BCSs complaining of dyspareunia and/or vaginal dryness, with more than 90% of subjects treated with anti-estrogenic adjuvant therapy (mostly AIs).<sup>41,45,47</sup> The initial publication in 2019 reported the feasibility of fractional micro ablative CO<sub>2</sub> as a GSM treatment, with 59 women having completed 3 vaginal and vulvar laser sessions without relevant AEs.<sup>41</sup> A significant improvement in subjective genital and urinary symptoms, as well as sexual function and distress, measured by the female sexual function index (FSFI) and the female sexual distress scale (FSDS), respectively, was found; even objective signs of VVA, including vaginal pH, improved but the level of significance was not mentioned.<sup>41</sup> Afterwards, a study amendment allowed investigators to prolong follow up to 12 and 24 months in order to evaluate lasting improvement over time; among 59 women who completed the original study, data from 39 and 33 women were collected at 12 and 24 months follow up, respectively. The median FSFI score was lower at 12 months compared with 4 weeks, but still significantly higher than at baseline, while there was a trend for FSDS score to decrease during the same time frame, suggesting a sustained improvement in sexual distress; no significant changes in FSFI and FSDS scores were observed between 12 and 24 months follow up.<sup>45</sup> A lingering positive effect of laser treatment was observed for genital but not for urinary symptoms.<sup>47</sup> A similar trend of response was reported by Veron et al in their study involving 46 BCSs, showing maximum improvement of sexual function and urinary distress at 2 and 6 months follow up, respectively; at 18

**Table 1** Summary of Included Studies on Fractional Micro Ablative Vaginal Laser in Breast Cancer Survivors (BCSs)

Author	n.	Characteristics of Patients (Pts)/ Inclusion Criteria	Age (Yrs)	Age at Menopause and/or Duration	Adjuvant Therapy for BC	Study Design	Therapeutic Protocol	Outcomes	Follow Up	AEs (n.)	Main Results and Conclusions
Pagano et al, 2016 <sup>33</sup>	26	Women with diagnosis of BC with VVA symptoms	42 (Median, range 20–62)	Not specified (1 woman with spontaneous menopause, 25 women with iatrogenic menopause because of BC treatment)	26 women on ET: <ul style="list-style-type: none"> <li>• TMX + ovarian suppression (25)</li> <li>• Als (1)</li> </ul>	Retrospective study	Three sessions every 30–40 days Area treated: not specified Setting: dot power 30 w, scan time 1000 $\mu$ s, dot spacing 1000 $\mu$ m, smart stack from 1 to 3	Self-reported measures: VAS score for each VVA symptom and for each procedure-related discomfort symptom Clinician assessment: genital examination	Every application and 30 days after completion of three cycles of treatment	No	After three cycles of laser treatment, the median VAS scores for dyspareunia, dryness, itching/stinging, and sensitivity during sexual intercourse were 78%, 80%, 75% and 86%, respectively, lower than baseline The median VAS score for intensity of discomfort during insertion of the probe, probe movements, and for laser-associated pain was 67%, 50% and 30%, respectively, lower after treatment
Pieralli et al, 2016 <sup>34</sup>	50	Women with iatrogenic menopause because of current or previous BC Presence of VVA related dyspareunia	53.3 (median, range 41–66)	6.6 (median time of menopause, range 1–17)	22 women on ET: <ul style="list-style-type: none"> <li>• Als (2)</li> <li>• TMX (20)</li> </ul>	Single arm prospective study	Three sessions every 30 days with vaginal probe Settings: dot power 30 w, dwell time 1000 $\mu$ s, dot spacing 1000 $\mu$ m and smart stack parameter 1	Self-reported measures: dyspareunia, satisfaction (VAS) Clinician assessment: VHI (including vaginal pH)	4 weeks after the last laser application	No	Significant improvement in dyspareunia at follow up 76% satisfied/very satisfied at follow up Significant improvement in VHI, with no differences between Als, TMX-treated groups and untreated group

(Continued)

Table 1 (Continued).

Author	n.	Characteristics of Patients (Pts)/ Inclusion Criteria	Age (Yrs)	Age at Menopause and/or Duration	Adjuvant Therapy for BC	Study Design	Therapeutic Protocol	Outcomes	Follow Up	AEs (n.)	Main Results and Conclusions
Pagano et al, 2018 <sup>35</sup>	82	Women with a history of BC and VVA symptoms, after failure of vaginal moisturisers or lubricants	44 (median)	Not specified (10 women with spontaneous menopause, 72 with iatrogenic menopause)	61 women received ET: <ul style="list-style-type: none"> <li>• Als (37)</li> <li>• TMX (23)</li> </ul>	Retrospective study	Three sessions every 30–40 days Setting: a dot power of 30 W, scan time 1000 $\mu$ s, dot spacing 1000 $\mu$ m, smart stack parameter from 1 to 3	Self-reported measures: VAS score for each VVA symptom and for each procedure-related discomfort symptom Clinician assessment: genital examination	30 days after completion of three cycles of treatment	No	Differences in the mean VAS scores were significant for sensitivity during sexual intercourse, vaginal dryness, itching/stinging, dyspareunia, dysuria, bleeding, probe insertion, and movement-related pain Neither age and type of adjuvant systemic anticancer therapy seem to affect treatment outcome
Becorpi et al, 2018 <sup>36</sup>	20	Menopausal status History of BC VVA diagnosed if any of the following were present: (i) patient reported vaginal dryness; (ii) at least a clinically documented sign of VVA (flattening of the vaginal folds, dryness of the vaginal mucosa, pallor of the vaginal mucosa, fragility of the mucosa, and petechiae); (iii) vaginal pH>5.	58.2 (mean)	8.85 $\pm$ 5.54 (mean duration of menopausal status)	16 women used ET in the past	Single arm prospective study	Two sessions with vaginal probe Settings: 30-W power, dwell time of 1000 $\mu$ s, dot spacing of 1000 $\mu$ m, smart stack 1	Self-reported measures: clinical symptoms (VRS), treatment satisfaction (Likert scale), FSFI, FSDS Clinician assessment: VHI (including vaginal pH), vaginal microbiome and vaginal inflammatory cytokines pattern	30 days from second laser treatment	No	Significant improvement of VRS for all VVA symptoms, and FSFI; no significant changes in FSDS Significant improvement of VHI No significant changes in vaginal microbiome; significant changes in inflammatory and modulatory cytokines pattern towards a 'tissue remodeling' profile

Pearson et al, 2019 <sup>37</sup>	26	Women with a history of stage I–III BC Presence of at least one of the following VVA symptoms: vaginal dryness, itching, burning, dysuria and dyspareunia	55 (median)	Not reported	25 women received ET: <ul style="list-style-type: none"> <li>• TMX (12)</li> <li>• Als (11)</li> <li>• Als and ovarian suppression (1)</li> </ul>	Single arm pilot study	Three sessions every 4 weeks, with vaginal probe Settings: power 40 W, dwell time 1000 $\mu$ s and spacing of 1000 $\mu$ m with a smart stack of 2	Self-reported measures: VVA symptoms (VAS), FSFI, QoL (SF-12) and patient reported improvement in symptoms, sexual function, QoL (Likert scale) Clinician assessment: genital examination	4, 8, 12 weeks and 4 weeks after completion of the final treatment	Not reported	Significant improvement in VAS for all VVA symptoms (dryness, itch, burning, dysuria and dyspareunia) at 12 weeks Significant improvement in FSFI (total score and each domain) at 12 weeks 73% of patients reported an improvement of VVA symptoms, 50% in sexual function and 65% in QoL
Gittens et al, 2019 <sup>38</sup>	25	Women complaining of GSM symptoms with either spontaneous menopause or iatrogenic menopause secondary to ET for BC	55.2 $\pm$ 9.5 (mean $\pm$ SD)	47.3 $\pm$ 6.3 (mean age at menopause)	8 women on ET (type not specified)	Retrospective study	Three sessions every 6 weeks with vaginal and vulvar probes Setting: not reported	Self-reported measures: FSFI, FSDS and pain (WBFS9) overall and in each cohort (menopausal versus BCSs) Clinician assessment: genital examination	6 weeks after each treatment	No	Overall significant improvement in FSFI, FSDS, WBFS from baseline after 3 laser sessions Significant improvement in FSFI (total score and each domain), pain, dyspareunia and vaginal dryness domains of WBFS and FSDS in women with BC history after 3 laser sessions

(Continued)

Table I (Continued).

Author	n.	Characteristics of Patients (Pts)/ Inclusion Criteria	Age (Yrs)	Age at Menopause and/or Duration	Adjuvant Therapy for BC	Study Design	Therapeutic Protocol	Outcomes	Follow Up	AEs (n.)	Main Results and Conclusions
Angioli et al, 2020 <sup>39</sup>	165 (full cohort, 135 with BC history)	Women with a history of breast, ovarian, cervical, or uterus cancer At least one of the following symptoms of GSM: vaginal dryness, dyspareunia, vaginal pain at introitus, burning, or itching	53 (mean, range 31–73)	45 (mean age at menopause, range 31–54)	Not reported	Retrospective multicentric study	Three sessions every 30 days with vaginal probe Settings: dot power 40 w, dwell time of 1000 $\mu$ s and dot spacing of 1000 $\mu$ m	Self-reported measures: vaginal dryness, dyspareunia, vaginal introitus pain, burning, or itching (VAS) Clinician assessment: vaginal pH	4 weeks after the last laser application	No	Significant improvement in vaginal dryness (64%), dyspareunia (59%), vaginal introitus pain (52%), burning (68%), itching (71%) and vaginal pH (11%) in the overall, BCS and gynecological cancer survivors' cohorts of women
Hersant et al, 2020 <sup>40</sup>	20	Women with a history of BC VHI<15	56.1 $\pm$ 8.8 (mean $\pm$ SD)	51.25 $\pm$ 1.5 (mean age $\pm$ SD at menopause)	9 women treated with ET: <ul style="list-style-type: none"> <li>• TMX (2)</li> <li>• Als (4)</li> <li>• TAM followed by Als (3)</li> </ul>	Single arm feasibility study	2 sessions one month apart, with vaginal probe Settings: pulse width 0.9 ms, and energy density or fluence 11.5 J/cm <sup>2</sup>	Self-reported measures: FSD (FSDS), pain and satisfaction (VAS) Clinician assessment: VHI (including vaginal pH)	1, 3 and 6 months from first session	Two cases of moderate bleeding within 24 hours from procedure	Significant improvement of FSD score by 7% at 1 month, 35% at 3 months and 52% at 6 months compared with baseline Significant improvement of VHI by 21% at 1 month, 30% at 3 months and 34% at 6 months compared with baseline
Quick et al, 2020 <sup>41</sup>	67 (59 completed follow-up)	Women with BC stage I–III Self-reported dyspareunia and/or vaginal dryness of any severity	57.4 $\pm$ 9.5 years (mean $\pm$ SD)	Not reported	59 women treated with ET: <ul style="list-style-type: none"> <li>• Als (44)</li> <li>• TMX (13)</li> <li>• TMX and ovarian suppression (2)</li> </ul>	Single arm feasibility study	3 sessions every 30–45 days with vaginal and vulvar probe Setting: dot power 30 w, dwell time 1000 $\mu$ s, spacing 1000 $\mu$ m and smart stack parameter 1	Self-reported measures: FSFI, UDI-6, PGI-I Clinician assessment: VAS and VuAS scores + VHA (including vaginal pH)	At each session and after completion of the final treatment	No	59 women (88.1%) were able to complete the study Significant improvement in FSFI and UDI-6 at 4 weeks 39% of participants reported that their symptoms were a little better, 28.8% reported they were much better, and 22.0% reported they were very much better Significant improvement in total VAS and VuAS VHA improved from baseline to follow up (no level of significance reported)



Veron et al, 2021 <sup>42</sup>	46	Menopausal women with BC history and GSM symptoms	56 (median, range 45–59)	Not reported	36 current users of ET: <ul style="list-style-type: none"> <li>• 24 AIs</li> <li>• 6 AIs and ovarian suppression</li> <li>• 6 TMX</li> </ul>	Single arm prospective study	3 sessions every month, with vaginal probe Setting: dot power 26 to 40 w, dwell time of 1000 $\mu$ s, dot spacing of 1000 $\mu$ m, with increasing stack at each session (1–3)	Self-reported measures: FSFI, Ditrovie score and SF-12 for urinary and general QoL, respectively Clinician assessment: vaginal pH and vaginal epithelial maturation pattern	Last laser session, 6 and 18 months	Low grade (2) and high grade (1) HPV-linked cervical lesions	Significant improvement of all FSFI domains score at 6 months, followed by a decrease in all domains which remained significantly higher than baseline at 18 months, with the exception of pain and desire Significant improvement of Ditrovie score at 6 months, return to baseline scores at 18 months Global QoL remained unchanged Vaginal pH slightly decreased ( $\Delta = -0.3$ ), whereas maturation pattern did not show significant changes at follow up
Siliquini et al, 2021 <sup>43</sup>	135	<ul style="list-style-type: none"> <li>• 45 menopausal women with BC history</li> <li>• 90 age and BMI matched menopausal women without history of BC, with GSM symptoms</li> </ul>	60.6 $\pm$ 8.18 (mean $\pm$ SD, BC) 58.3 $\pm$ 8.40 (mean $\pm$ SD, controls)	Not reported	18 past users (10 TMX, 6 TMX and ovarian suppression, 2 AIs) 17 current users (5 TMX, 11 AIs, 1 AIs and ovarian suppression)	Retrospective cohort study	3 sessions every 30 days with vaginal and vulvar probes Setting: dot power 40 watts with smart stack 3 at vaginal level, 25–35 watts with smart stack 1 at introital level and 20–30 watts with smart stack 1 at vulvar level	Self-reported measures: dyspareunia, vaginal dryness severity, pain with the procedure (VAS) Clinician assessment: VHI (including vaginal pH), VVHI	30 days after each session, 3, 6 and 12 months after last session	No	Significant improvement in vaginal dryness and dyspareunia severity from 3 months follow up in both groups, persisting at 12 months follow up; improvement was slower in BCS compared with controls. Significant improvement in VHI and VVHI at any session and maintained through the 12-month follow up; VHI reached scores of normal trophism after 2 sessions in BCS and one session in control group.

(Continued)

Table I (Continued).

Author	n.	Characteristics of Patients (Pts)/ Inclusion Criteria	Age (Yrs)	Age at Menopause and/or Duration	Adjuvant Therapy for BC	Study Design	Therapeutic Protocol	Outcomes	Follow Up	AEs (n.)	Main Results and Conclusions
Salvatore et al, 2021 <sup>44</sup>	40	Women with a history of BC Past or current treatment with ET Symptoms of VVA (vaginal dryness, vaginal burning, vaginal itching, dyspareunia, and dysuria)	57.6±7.2 (mean±SD)	49.5±4.6 years (mean age at menopause ±SD)	25 past ET users (Group 1) 15 current ET users (Group 2) Type of ET not reported	Prospective cohort study	5 sessions every 4 weeks with vaginal probe Settings: dot power 30 watts, dwell time 1000 µs, dot spacing 1000 µm, and smart stack parameter from 1 to 3	Self-reported measures: satisfaction (Likert scale), VVA symptoms severity (VAS), FSFI, QoL (SF12) Clinician assessment: VHI (including vaginal pH)	30, 60, 90, 120, 150 days	No	Six (15.0%) women were very satisfied, 25 (62.5%) were satisfied, 6 (15.0%) were uncertain, and 3 (7.5%) were dissatisfied at 20-week follow up Significant improvement in VVA symptoms severity, VHI, all FSFI domains, physical and mental domains of SF12, with no significant differences between study groups at 20-week follow up
Quick et al, 2021 <sup>45</sup>	67 (59 completed 4 weeks and 39 completed 1 year follow ups)	Women with BC stage I–III Self-reported dyspareunia and/or vaginal dryness of any severity	57.4±10.5 (mean±SD)	Not reported	37 women on ET: • Als (26) • TMX (9) • TMX and ovarian suppression (2)	Single arm prospective study	3 sessions every 30–45 days with vaginal and vulvar probe Setting: dot power 30 w, dwell time 1000 µs, spacing 1000 µm and smart stack parameter 1	Self-reported measures: FSFI, FSDS Clinician assessment: genital examination	4 weeks after last session and 1 year	No	Significant improvement of FSFI and FSDS from baseline to 4-week follow up At 12 months, FSFI was significantly reduced compared with 4-week follow up, but higher compared with baseline No significant changes of FSDS observed at 12 months compared with 4-week follow up

Gardner et al, 2021 <sup>46</sup>	139 (full cohort, 38 with BC history)	Women who completed 2 sessions of fractional micro ablativ CO2 laser for bothersome symptoms of VVA	62±10 (mean ±SD, full cohort)	12.6±9.45 (mean±SD duration of menopause)	19 of BC women on ET: <ul style="list-style-type: none"> <li>• AI (15)</li> <li>• TMX (4)</li> </ul>	Retrospective study	3 sessions every 6 weeks with vaginal and vulvar probe Settings: dot power 30 watts, dwell time 1000 µs, dot spacing 1000 µm, smart stack from 1 to 3	Self-reported measures VVA symptoms (VSQ), pain with VVA symptoms (VAS), FSFI Clinician assessment: genital examination	About 13 weeks from baseline	No	In BCSs group, significant improvement in 18 of the VSQ questions and in VAS for 5 symptoms (vaginal pain, itching, burning, dryness, painful intercourse, but not painful urination), and in FSFI (total score and all six domains), similar to general cohort
Quick et al, 2022 <sup>47</sup>	67 (64 started, 39 completed 1 year, 33 completed 2 years)	Women with history of BC stage I–III Self-reported dyspareunia and/or vaginal dryness of any severity	59.3±10.8 (mean±SD)	Not reported	32 women on ET: <ul style="list-style-type: none"> <li>• Als (23)</li> <li>• TMX (7)</li> <li>• TMX and ovarian suppression (2)</li> </ul>	Single arm prospective study	3 sessions every 30–45 days with vaginal and vulvar probe Setting: dot power 30 w, dwell time 1000 µs, spacing 1000 µm and smart stack parameter 1	Self-reported measures: VAS and VuAS score, FSFI, FSDS, UDI-6 Clinician assessment: genital examination	4 weeks, 1 and 2 years	No	No significant difference in VAS and VuAS score and sexual function compared with the improvement at 4-week follow up. No significant changes in FSFI and FSDS compared with the improvement at 4-week follow up and values at 12-month follow up UDI-6 approached baseline scores

(Continued)

Table 1 (Continued).

Author	n.	Characteristics of Patients (Pts)/ Inclusion Criteria	Age (Yrs)	Age at Menopause and/or Duration	Adjuvant Therapy for BC	Study Design	Therapeutic Protocol	Outcomes	Follow Up	AEs (n.)	Main Results and Conclusions
Mension et al, 2023 <sup>48</sup>	72	Women with a history of BC currently treated with AIs Menopausal status, with signs or symptoms of GSM, including dyspareunia and vaginal pH>5 Self-reported willingness of being sexually active	51.3 years (laser-treated group); 53.7 years (sham-treated group)	44.7 years (laser-treated group); 45.6 years (sham-treated group)	Aromatase inhibitor therapy ongoing for at least 6 months	Prospective, randomized, double-blind, sham-controlled trial	Two arms randomly assigned: <ul style="list-style-type: none"> <li>35 women: 5 monthly sessions of intravaginal CO<sub>2</sub> laser. Setting: dot power 40 w, dwell time 1000 μs, dot spacing 1000 μm.</li> <li>37 women: 5 monthly sessions with intravaginal sham probe. Setting: dot power 0 w, dwell time 100 μs, dot spacing 2000 μm.</li> </ul> All patients instructed to use daily external moisturizer, intravaginal moisturizer pessaries every 3 days and vaginal vibrator twice/week	Self-reported measures: FSFI (primary outcome), VAS for dyspareunia, SF-12, Spanish body image scale, Likert scale for tolerance Clinician assessment: VHI Objective outcomes: vaginal pH, VMI, VEE (Pascal), VET (mm), circulating E2	6 months	13 women in laser group and 10 women in sham group, intensity rated mild (45%, spotting, vaginal itching) to moderate (10%, urinary tract infection)	Improvement in most of subjective and objective outcomes in both groups, with the exception of quality of life and vaginal epithelial thickness, without any significant difference between laser-treated and sham-treated groups Laser treatment significantly less tolerated than sham treatment

**Abbreviations:** AEs, adverse events; AIs, aromatase inhibitors; BC, breast cancer; E2, estradiol; ET, endocrine therapy; FSFI, female sexual function index; FSD, female sexual dysfunction; FSIDS, female sexual distress scale; PGI-I, patient global impression of improvement; QoL, quality of life; SF-12, short form 12; TMX, tamoxifen; UDI-6, urinary distress inventory, short form; VHA, vaginal health assessment; VAS, visual analogue scale; VAS and VuAS, Vaginal and Vulvar Assessment Scales; VEE, vaginal epithelial elasticity; VET, vaginal epithelial thickness; VRS, verbal rating scale; VHI, vaginal health index; VMI, vaginal maturation index; VSQ, vaginal symptoms questionnaire; VVA, vulvovaginal atrophy, VVHI, vulvovaginal health index; WBFS, Wong-Baker FACES scale.

**Table 2** Summary of Included Studies on Non-Ablative Vaginal Erbium Laser in Breast Cancer Survivors (BCSs)

Author	n.	Characteristics of Patients (Pts)/ Inclusion Criteria	Age (Yrs)	Age at Menopause and/or Duration	Adjuvant Therapy for BC	Study Design	Therapeutic Protocol	Outcomes	Follow Up	AEs (n.)	Main Results and Conclusions
Gambacciani et al, 2017 <sup>49</sup>	43	Postmenopausal women with BC history reporting symptoms of GSM	50.8±8.1 (mean ±SD)	43.2±5.0 years (mean)	Not reported	Pilot, prospective, longitudinal study	3 sessions every 30 days with vaginal probe Settings: frequency 1.6 Hz, fluence 6.0 J/cm <sup>2</sup>	Self-reported measures: dryness and dyspareunia (VAS) Clinician assessment: VHI score (including vaginal pH)	Following each session and after 1, 3, 6, 12 and 18 months	No	Significant decrease in VAS for dryness, dyspareunia and increase in VHI up to 12 months compared to baseline
Mothes et al, 2017 <sup>50</sup>	16	BCSs complaining symptoms of VVA after surgery for pelvic organ prolapse	71±7 (mean ±SD)	Not reported	Not reported	Retrospective study	Single 10-min course vaginal erbium laser Setting: fluence between 15 and 35 J/m <sup>2</sup> (phase I) and 3 and 9 J/m <sup>2</sup> (phase II)	Self-reported measures: Overall satisfaction Clinician assessment: VHI, vaginal pH	8.3 ±2 weeks (mean ±SD)	Not reported	94% of patient satisfied with the procedure Significant improvement of VHI
Arêas et al, 2019 <sup>51</sup>	24	Menopausal women with history of BC Presence of vaginal dryness and/or dyspareunia	53.7 ±9.66 (mean ±SD)	7.92±5.94 years (mean±SD, duration of menopause)	60% currently treated with TMX	Open prospective intervention study	Three sessions every 30 days, with vaginal probe Settings: fluence 2.0 J/cm <sup>2</sup> , frequency 0.5 Hz, pulses using the smooth-mode technique (eight pulse trains of 50 ms totaling 400 ms)	Self-reported measures: SPEQ Clinician assessment: VHI (including vaginal pH)	Before laser session and after 1 month following the last	Vaginal candidiasis (1) and acute cystitis (1)	Significant improvement of SPEQ, with significant effect size for total score and dyspareunia, and of VHI

(Continued)

Table 2 (Continued).

Author	n.	Characteristics of Patients (Pts)/ Inclusion Criteria	Age (Yrs)	Age at Menopause and/or Duration	Adjuvant Therapy for BC	Study Design	Therapeutic Protocol	Outcomes	Follow Up	AEs (n.)	Main Results and Conclusions
Gold et al, 2022 <sup>52</sup>	43	Women with a history of BC with at least one of the following symptoms: vaginal dryness, burning or irritation; lack of lubrication during sexual intercourse/ sexual discomfort or pain; symptoms of urgency and dysuria; recurrent urinary tract infection	54 (median, range 49–58)	Not reported (9 women premenopausal, 34 women postmenopausal)	32 women on current ET: <ul style="list-style-type: none"> <li>• AIs (25)</li> <li>• TMX (7)</li> </ul>	Single centre, randomized, controlled trial	Two arms randomly assigned: <ul style="list-style-type: none"> <li>• 22 women: intravaginal non-ablative erbium laser (2 sessions within one month; intra-vaginal application; fluence 20 J/cm<sup>2</sup>)</li> <li>• 21 women: hyaluronic acid suppositories (3 time/week for 3 months)</li> </ul>	Self-reported measures: Subjective bother of urogenital atrophy and degree of discomfort or pain during laser therapy (NRS), PGI-I e PGI-S, EORTC-QLQ-BR45, EORTC SHQ-C22, Australian pelvic floor questionnaire Clinician assessment: VHI (including vaginal pH)	3 months	No	Significant improvement of urogenital atrophy associated bother in both groups without significant differences between laser and suppositories; dyspareunia and OAB associated bother decreased in both groups, SUI associated bother decreased in laser group only PGI-I improved slightly in both groups; PGI-S decreased only in the laser group Several domains of EORTC-QLQ-BR45 improved in both groups. Only sexual pain multi-domains item decreased in the laser group, whereas sexual satisfaction and other single domains did not change in any of the two groups Significant improvement of VHI

**Abbreviations:** AEs, adverse events; AIs, aromatase inhibitors; BC, breast cancer; BCSs, breast cancer survivors; ET, endocrine therapy; EORTC-QLQ-BR45, European organization for research and treatment of cancer-quality of life questionnaire; EORTC-SHQ-C22, European Organization for Research and Treatment of Cancer-Sexual Health Questionnaire; GSM, genitourinary syndrome of menopause; NRS, numerical rating scale; OAB, overactive bladder; PGI-I, patient global impression of improvement; PGI-S, patient global impression of severity; SPEQ, Short Personal Experiences Questionnaire; SUI, stress urinary incontinence; TMX, tamoxifen; VAS, visual analogue scale; VHI, vaginal health index; VVA, vulvovaginal atrophy.

months, sexual function decreased but remained significantly higher than at baseline, with the exception of pain and desire domains, whereas urinary distress almost reverted to pre-treatment scores.<sup>42</sup>

Several prospective studies reported current or past use of anti-estrogenic adjuvant therapy but only a few of them investigated the impact of these drugs on laser treatment response. In a recent prospective feasibility study, a population of 20 BCSs was divided into 2 groups, according to the past (group 1) and current (group 2) use of anti-estrogenic adjuvant therapy.<sup>44</sup> The authors proposed a protocol with increased number of laser sessions (5 rather than 3) and a progressive increase in laser energy, based on the assumption that severely atrophic vaginal mucosa in BCSs may require a gradual and prolonged exposure for optimal response. At 20-week follow up, more than 70% of women considering the whole sample were satisfied with treatment and both groups reported a similar significant improvement of vulvovaginal symptoms.<sup>44</sup> Also sexual function and quality of life (QoL), assessed through the FSFI and the 12-items short form survey (SF-12), respectively, significantly improved in a similar manner between the two groups.<sup>44</sup> Pieralli et al conducted the only study prospectively investigating the effect of different types of anti-estrogenic adjuvant therapy or no treatment in a sample of 50 BCSs with oncological menopause and reporting dyspareunia related to VVA.<sup>34</sup> A significant improvement in median VHI across all groups, irrespective of the use and type of anti-estrogenic adjuvant therapy, was found; of note, only 2 BCSs were assuming AIs and 20 were on TMX.<sup>34</sup> Other pilot studies found improvement of GSM symptoms<sup>37,40,41</sup> and sexual function<sup>37,40</sup> or distress<sup>41</sup> in women using different types of anti-estrogenic adjuvant therapy, but the small sample size did not allowed subgroup analyses.

Becorpi et al published a study on a small sample of menopausal BCSs who completed various adjuvant treatments, with the aim to investigate the impact of CO<sub>2</sub> laser on vaginal microbiome and cytokine profile and their role in improving GSM symptoms.<sup>36</sup> No change in composition of vaginal microbiome was documented after CO<sub>2</sub> laser treatment, despite an improvement in clinical signs and symptoms, whereas a significant change in cytokines secretory pattern was evident after laser treatment. The reduced concentration of some pro-inflammatory cytokines (IL2 and IL-7) and the increase of some cytokines and growth factors involved in tissue remodeling (IL-18, CTACK, LIF, M-CSF) suggested local immunity as a possible mediator of the effect of CO<sub>2</sub> laser on vaginal mucosa.<sup>36</sup>

The results of a double-blind, randomized, sham-controlled trial specifically evaluating efficacy of vaginal CO<sub>2</sub> in a sample of BCSs on AIs therapy have been recently published.<sup>48</sup> The primary objective of the study was to identify differences in sexual function changes (evaluated through FSFI) after 5 sessions of vaginal CO<sub>2</sub> laser versus an inactive sham treatment.<sup>48</sup> Of note, participants from both groups were instructed to use non-hormonal local moisturizing therapy and vaginal vibrator throughout the study period, and possibility of sexual counselling was offered to each patient. Overall, in the whole cohort the authors reported a significant improvement in sexual function and in most of the secondary subjective (VAS scale for dyspareunia, Spanish Body Image scale, VHI) and objective (vaginal pH, vaginal maturation index and histologically evaluated vaginal epithelial elasticity) outcomes, with the exception of quality of life and vaginal epithelial thickness; however, there was no statistically significant difference between the two treatment arms.<sup>48</sup>

## Non-Ablative Erbium Laser

Four studies<sup>49–52</sup> specifically assessed efficacy and safety of vaginal erbium laser in BCSs, with variable study protocols (1–3 laser sessions) and energy settings (see Table 2). In a prospective longitudinal pilot study involving 43 menopausal BCSs with GSM symptoms, Gambacciani et al described improvement in subjective VAS scores for vaginal dryness and dyspareunia and in VHI scores at 12-month follow up after 3 sessions of vaginal erbium laser.<sup>49</sup> A not statistically significant trend for persistence of beneficial effects after 18 months from the last laser application was evident.<sup>49</sup> An improvement in VHI scores was also observed after a single vaginal erbium application in the study of Mothes et al, with 94% of subjective satisfaction; however, the sample size was very small and included an old BCSs sub-population who had a previous surgery for prolapse.<sup>50</sup> In another small sample of menopausal BCSs who were in half of the cases on current TMX therapy, Arêas et al reported a significant improvement in VHI score and sexual function measured by the Short Personal Experiences Questionnaire (SPEQ), with study follow up limited to one month.<sup>51</sup>

A recent randomized trial by Gold et al reported a comparison between vaginal erbium laser and local hyaluronic acid in BCSs with urogenital atrophy; they enrolled 43 women, with either vaginal dryness, dyspareunia, urgency/dysuria and/or recurrent urinary tract infections, who were randomly allocated to vaginal erbium laser (2 sessions 30 days apart) or to

hyaluronic acid vaginal suppositories (daily for 10 days and then three times a week for 12 weeks in total).<sup>52</sup> At 12 weeks follow-up, there was a significant improvement in VHI in both arms, without any difference between erbium laser and hyaluronic acid.<sup>52</sup> Moreover, bother related to symptoms of urogenital atrophy, dyspareunia and urgency appeared significantly reduced after both interventions, whereas stress urinary incontinence was significantly less bothersome only following laser treatment.<sup>51</sup> Several domains of QoL were improved in both treatment arms, while sexual satisfaction and other domains of sexual function did not change, with the exception of sexual pain which improved only following laser treatment. Patients in both groups reported a slight subjective impression of improvement [evaluated through patient global impression of improvement (PGI-I)].<sup>52</sup> Overall, the authors concluded that both hyaluronic acid and vaginal erbium laser were safe options to manage GSM-related symptoms, with superimposable outcomes.<sup>52</sup>

## Discussion

Overall, the studies included in [Table 1](#) and [Table 2](#) support a positive impact of vaginal laser treatment on signs and symptoms of GSM in the outpatient setting, with no relevant AEs and a high rate of tolerability which improved with treatment cycles. Around 700 BCSs have been treated mostly in monocentric studies with small sample size, uncontrolled designs and short follow-up times. The majority of studies<sup>33–35,37–39,41–43,45–47</sup> performed a total of 3 laser sessions over around 3 months. Clinical characteristics of BCSs were quite heterogeneous, as well as treatment protocols and study outcomes. Duration of effects seemed to last up to 6<sup>40,42,44</sup> and 12 months.<sup>43,45,47,49</sup> Retrospective comparisons in cross-sectional studies<sup>38,43,46</sup> not showing significant difference in efficacy of CO<sub>2</sub> laser between healthy menopausal women and BCSs were of limited value. According to one study, it seemed likely that a higher number of laser sessions are needed to obtain better results in BCSs.<sup>44</sup> The paucity of AEs in BCSs<sup>40,42,48,51</sup> was reassuring but evidence of few cases reporting complications such as fibrosis, scarring, agglutination, and penetration injury in healthy menopausal women<sup>53</sup> required long-term follow up especially in women severely deprived of estrogens and, therefore, at potential higher risk of complications due to more fragile tissues.<sup>4,5</sup> The procedure was generally well tolerated, but tolerance was significantly lower for CO<sub>2</sub> laser than sham in the comparative study.<sup>48</sup> When clearly reported in studies,<sup>44,50</sup> satisfaction with laser procedures was high.

As indicated in previous systematic<sup>54–56</sup> and narrative reviews,<sup>57</sup> we confirmed that several key questions still await to be answered before vaginal laser treatment may be fully recognized for clinical use on a large scale. Vaginal laser treatment might be effective in treating GSM in BC survivors in the short term but the quality of evidence was rated “very low” in BC survivors and other oncological samples with sexual problems.<sup>58</sup>

Recent systematic reviews and meta-analyses of studies in healthy menopausal women with GSM diagnosis treated with different CO<sub>2</sub>-laser devices and technologies reached similar conclusions.<sup>59–61</sup> On the other hand, when only the few randomized clinical trials that compared CO<sub>2</sub> laser with sham among healthy menopausal women with GSM diagnosis were included, a significant improvement of vaginal, sexual and urinary scores with a high rate of satisfaction was reported.<sup>62</sup> Moreover, a small pilot, multi-institutional randomized sham-controlled trial of women with gynecological cancers with dyspareunia and/or vaginal dryness did not show a significant effect on subjective GSM symptoms, other than a mild significant effect on sexual function, but noted some physical exam improvements in the active treatment arm and supported safety.<sup>63</sup> However, the most recent double-blinded sham-controlled randomized trials in healthy menopausal women found a similar improvement of GSM symptoms following sham or laser treatment,<sup>64–66</sup> a finding replicated in the recent trial of Mension et al, the first sham controlled one to include BCSs, more specifically those at higher risk of severe genital symptoms because of AIs therapy.<sup>48</sup> An insightful state-of-the-art review<sup>67</sup> concluded that the effect of vaginal and vulvar laser treatment decreased with higher study quality and only eliminating potential bias with an adequate statistical power, in comparison with approved GSM treatments and sham lasers, will help to solve the issue. Placebo and sham-intervention conditioning effects might also interfere with clinical results depending on the quality of the outcomes.<sup>68</sup> Indeed, potential subsets of patients, i.e. those with vaginal dryness as most bothersome symptoms, may benefit to a higher extent following laser as compared with sham.<sup>66</sup>

Interestingly, an experimental model of VVA induced by iatrogenic menopause in the ewe failed to show substantial differences between tissues treated with sham manipulations or non-ablative erbium laser sessions and supported a more prominent increase in epithelial thickness and higher vaginal compliance in estrogen-replaced ewes.<sup>69</sup> This has been partially confirmed in the study by Mension et al, showing no effect of either CO<sub>2</sub> laser or sham treatment on vaginal



epithelial thickness and a comparable improvement in vaginal epithelial elasticity in both treatment arms.<sup>48</sup> On the other hand, histological findings deriving from both CO<sub>2</sub> and erbium vaginal laser treatments,<sup>70</sup> as well as measurement of increased epithelial thickness, have been available in clinical samples.<sup>71,72</sup> Moreover, iconographic representations, i.e. colposcopy images, documented beneficial effects of laser treatment on vulvovaginal tissues<sup>36,73</sup> supporting both safety and satisfaction reported in the majority of the studies included in Tables 1<sup>33–48</sup> and 2<sup>49–52</sup> and in other clinical samples treated for GSM.<sup>74,75</sup> Even so, the correlation between tissue changes induced by laser treatment and clinical outcomes has been questioned<sup>76</sup> and controversy might be solved in study designs with laser technology that will take into account the complex interplay of subjective factors influencing the clinical relevance of treating objective signs.<sup>77</sup>

Of note, as an item of the vaginal health index (VHI), a validated scale to rate GSM signs subjectively by HCPs,<sup>78</sup> vaginal pH was the only objective GSM parameter associated with vaginal hypoestrogenism<sup>2</sup> that has been measured before and after CO<sub>2</sub> laser in some studies in BCSs<sup>34,36,39–44,48</sup> and in all studies with erbium laser.<sup>49–52</sup> The vaginal maturation index (VMI), the other supporting finding of GSM diagnosis which quantifies the percentages of parabasal, intermediate, and superficial cells, indirectly estimating the pattern of tissue hypoestrogenism,<sup>2</sup> was considered only in two studies with CO<sub>2</sub> laser, being unchanged from baseline to follow up in the study of Vernon et al and improved in the controlled trial of Mension et al, but without significant differences between laser and sham group.<sup>42,48</sup> Even though vaginal pH and VMI are routinely assessed in clinical trials to prove effects of a given treatment on the vaginal epithelium, they are not essential to make a clinical diagnosis.<sup>79</sup> In future investigations at baseline and under sham or laser treatment, an objective noninvasive tool to assess severity of GSM signs might be 3D high frequency vaginal ultrasound (US), which allows measuring of the anterior and posterior walls of the vagina separately.<sup>80</sup> Indeed, at variance with transabdominal US-measured vaginal wall thickness or total mucosal thickness which did not show a difference between GSM symptomatic and asymptomatic women,<sup>81</sup> 3D vaginal US displayed correlations with age, time since menopause and sexual domains (arousal, lubrication, pain, and satisfaction) in a pilot study conducted in women with and without GSM symptoms.<sup>80</sup> Other objective indicators may be changes of the vaginal microbiota and inflammatory factors according to some evidence<sup>36,82,83</sup> that needs to be further confirmed.

At present, bothersome symptoms, namely pain with sex, vulvovaginal dryness, vulvovaginal discomfort or irritation, and discomfort or pain when urinating, should be the core outcomes guiding research trials and clinical practice in order to manage GSM effectively.<sup>84</sup> As a matter of fact, a significant number of menopausal women reported a plethora of GSM symptoms with an impact on urogenital health, QoL and sexual function that was not consistent with the severity of GSM at genital examination.<sup>85–87</sup> This could translate in a delay in receiving effective care because menopausal women under appropriate treatment reported significantly more frequent and severe GSM symptoms in comparison with those who were untreated.<sup>88</sup> Interestingly, in a sample of menopausal women with a history of breast or endometrial cancer who sought treatment for vulvovaginal symptoms, clinical gynecological exam findings did not correlate with the information reported by the patient about vulvovaginal dryness and discomfort.<sup>89</sup> Data regarding the effects of CO<sub>2</sub> (Table 1) and erbium (Table 2) laser in BCSs were mostly on typical VVA symptoms, whereas urinary symptoms were poorly explored with validated scales.<sup>41,42,47,52</sup> As far as sexual dysfunction was concerned, sexual function changes following CO<sub>2</sub> laser treatment were measured in several studies (Table 1) by a validated scale (female sexual function index, FSFI)<sup>36–38,41,42,44–48</sup> with psychometric properties that have been recently reassessed in BCSs,<sup>90</sup> whereas changes of sexual distress (female sexual distress scale, FSDDS), an essential element to establish the clinical relevance of sexual symptoms,<sup>91</sup> were measured only in 5 studies following CO<sub>2</sub> laser treatment (Table 1).<sup>36,38,40,45,47</sup> Only in one study with erbium laser<sup>52</sup> (Table 2) psychometric tools validated in the oncologic setting were used. Therefore, high-quality randomized clinical trials and long-term follow up are warranted in BCSs with a GSM clinical diagnosis, taking into account the biopsychosocial challenges affecting sexual health, intimacy and QoL.<sup>92,93</sup> Appropriate sexual health screening tools, including cancer and treatment-specific questions, and QoL instruments validated in BCSs should be used to measure patient-reported outcomes and provide comprehensive care.<sup>94,95</sup> Indeed, the oncological setting amplified the needs of a multidimensional unique model of care to address menopausal symptoms and sexual problems including conventional and nonconventional medications, stress management, pelvic floor exercises and any other behavioral strategy able to target self-efficacy.<sup>96–99</sup>

It is important to underline that local hyaluronic acid, a non-hormonal treatment able to improve vaginal health in menopausal women,<sup>100</sup> was the only comparator used in BCSs so far with effects superimposable to those of erbium laser.<sup>52</sup> Results did not seem so convincing in light of several methodological shortcomings including substantial differences in treatment delivery and adherence.<sup>53</sup> Comparative studies with other non-hormonal approaches would be similarly limited by the fact that most of them have been predominantly studied in healthy postmenopausal women and there is a paucity of efficacy data supporting the use of a standard treatment for GSM in BCSs.<sup>101</sup> Implementation of adequately powered double-blinded sham-controlled trials appears the ideal solution to establish efficacy and safety in BCSs taking into account age, body mass index, smoking, pre- or postmenopausal status at the time of diagnosis, time since menopause, previous hormone use, type of chemotherapy and current or past use of anti-estrogenic adjuvant therapies, type of most bothersome symptoms, as well as their duration and severity, frequency of sexual activity, partnership, and any other aspect with relevance in GSM diagnosis. Indeed, studies reported in Tables 1<sup>33–48</sup> and 2<sup>49–52</sup> were underpowered to perform meaningful statistical analyses regarding some of these variables that might affect clinical outcomes. Finally, limitations in prescribing hormonal treatments as comparators of laser treatment in BCSs with a history of estrogen-dependent tumors should also be considered. Hormonal treatments may be used after the failure of non-hormonal treatments in women taking TMX and prescribed in women taking AIs after shared decision-making with patient, gynecologist and oncologist.<sup>18–22</sup>

In the cohort published by Gardner & Aschkenazi<sup>46</sup> (Table 1), there was a retrospective comparison between topical estrogen and two CO<sub>2</sub> laser sessions showing a not statistically significant difference following 13 weeks when treatments were concomitant. A systematic review and meta-analysis including randomized clinical trials (RCTs) that compared the use of fractional CO<sub>2</sub> laser with standard estrogen therapies (conjugated estrogens, estriol, promestriene) showed almost superimposable positive outcomes on GSM signs and symptoms evaluated with subjective and objective measurements.<sup>102</sup> Also comparison of laser therapy with other hormonal treatments potentially safe in BCSs, such as vaginal prasterone<sup>103</sup> and oral ospemifene,<sup>104</sup> may expand the range of treatment options available in menopausal women<sup>105</sup> and in high-risk patients with GSM.<sup>106</sup> An aspect deserving further investigation is the possibility to combine laser therapy with other treatment strategies to maximize and/or maintain long-term positive effects. This approach could balance risks and benefits in BCSs, taking into account level of evidence and women's preferences, as well as containing elevated costs for the healthcare system.

This systematic review has limitations that need to be considered. Some studies did not provide information about clinical characteristics, including data about menopausal stage or use and type of adjuvant endocrine therapy, which appear relevant in the authors' view to interpret the results. Other studies' characteristics, including design, sample size and outcome heterogeneity, have been acknowledged as major factors limiting the quality of available data.

## Conclusions

Effective management of GSM is one of the pillars of menopausal care to enhance sexual well-being and QoL.<sup>107</sup> BC alone accounts for almost one-third of all incident cases of cancer in the US in 2022 with 5-year relative survival rates of 90% in women.<sup>108</sup> Given GSM is a chronic heterogeneous condition highly prevalent as women age,<sup>109</sup> the unmet medical need for safe GSM therapies remains large in BCSs. Vaginal laser therapy represents a great opportunity to fill the gap providing symptoms relief and restoring tissues, in the meantime avoiding estrogen exposure. Available data are reassuring in the short term and indicate effectiveness of both CO<sub>2</sub> and erbium lasers on the most common GSM symptoms. However, further studies are mandatory to prove long-term efficacy and safety in menopausal women, including BCSs. Very importantly, it remains to be established who are the women that might benefit most from these minimally invasive techniques according to their own specific properties.<sup>26,110</sup>

## Disclosure

Professor Rossella E. Nappi had past financial relationships (lecturer, member of advisory boards and/or consultant) with Boehringer Ingelheim, Ely Lilly, Endoceutics, Merck Sharpe & Dohme, Palatin Technologies, Pfizer Inc, Procter & Gamble Co, TEVA Women's Health Inc. and Zambon SpA. At present, she has ongoing relationships with Abbott, Astellas, Bayer HealthCare AG, Exceltis, Fidia, Gedeon Richter, HRA Pharma, Novo Nordisk, Organon & Co, Shionogi Limited and Theramex, outside the submitted work. The authors report no other conflicts of interest in this work.

## References

1. Shifren JL. Genitourinary syndrome of menopause. *Clin Obstet Gynecol.* 2018;61(3):508–516. doi:10.1097/GRF.0000000000000380
2. Portman DJ, Gass ML; Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society. *Menopause.* 2014;21(10):1063–1068. doi:10.1097/GME.0000000000000329
3. Simon JA, Goldstein I, Kim NN, et al. The role of androgens in the treatment of Genitourinary Syndrome of Menopause (GSM): International Society for the Study of Women's Sexual Health (ISSWSH) expert consensus panel review. *Menopause.* 2018;25(7):837–847. doi:10.1097/GME.0000000000001138
4. Falk SJ, Bober S. Vaginal Health During Breast Cancer Treatment. *Curr Oncol Rep.* 2016;18(5):32. doi:10.1007/s11912-016-0517-x
5. Cox P, Panay N. Vulvovaginal atrophy in women after cancer. *Climacteric.* 2019;22(6):565–571. doi:10.1080/13697137.2019.1643180
6. Nappi RE, Martini E, Cucinella L, et al. Addressing Vulvovaginal Atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) for healthy aging in women. *Front Endocrinol.* 2019;10:561. doi:10.3389/fendo.2019.00561
7. Lester J, Pahouja G, Andersen B, Lustberg M. Atrophic vaginitis in breast cancer survivors: a difficult survivorship issue. *J Pers Med.* 2015;5(2):50–66. doi:10.3390/jpm5020050
8. Crean-Tate KK, Faubion SS, Pederson HJ, Vencill JA, Batur P. Management of genitourinary syndrome of menopause in female cancer patients: a focus on vaginal hormonal therapy. *Am J Obstet Gynecol.* 2020;222(2):103–113. doi:10.1016/j.ajog.2019.08.043
9. Biglia N, Cozzarella M, Cacciari F, et al. Menopause after breast cancer: a survey on breast cancer survivors. *Maturitas.* 2003;45(1):29–38. doi:10.1016/s03785122(03)00087-2
10. Santen RJ, Stuenkel CA, Davis SR, Pinkerton JV, Gompel A, Lumsden MA. Managing menopausal symptoms and associated clinical issues in breast cancer survivors. *J Clin Endocrinol Metab.* 2017;102(10):3647–3661. doi:10.1210/jc.2017-01138
11. Smith KL, Verma N, Blackford AL, et al. Association of treatment-emergent symptoms identified by patient-reported outcomes with adjuvant endocrine therapy discontinuation. *NPJ Breast Cancer.* 2022;8(1):53. doi:10.1038/s41523-022-00414-0
12. Nappi RE, Palacios S, Bruyniks N, Particco M, Panay N; EVES Study Investigators. The European Vulvovaginal Epidemiological Survey (EVES). Impact of history of breast cancer on prevalence, symptoms, sexual function and quality of life related to vulvovaginal atrophy. *Gynecol Endocrinol.* 2021;37(1):78–82. doi:10.1080/09513590.2020.1813273
13. Cook ED, Iglehart EL, Baum G, Schover LL, Newman LL. Missing documentation in breast cancer survivors: genitourinary syndrome of menopause. *Menopause.* 2017;24(12):1360–1364. doi:10.1097/GME.0000000000000926
14. Lindau ST, Abramssohn EM, Matthews AC. A manifesto on the preservation of sexual function in women and girls with cancer. *Am J Obstet Gynecol.* 2015;213(2):166–174. doi:10.1016/j.ajog.2015.03.039
15. Kingsberg SA, Larkin L, Krychman M, Parish SJ, Bernick B, Mirkin S. WISDOM survey: attitudes and behaviors of physicians toward vulvar and vaginal atrophy (VVA) treatment in women including those with breast cancer history. *Menopause.* 2019;26(2):124–131. doi:10.1097/GME.0000000000001194
16. Biglia N, Bounous VE, D'Alonzo M, et al. Vaginal atrophy in breast cancer survivors: attitude and approaches among oncologists. *Clin Breast Cancer.* 2017;17(8):611–617. doi:10.1016/j.clbc.2017.05.008
17. Biglia N, Del Pup L, Masetti R, Villa P, Nappi RE. Vulvovaginal atrophy (VVA) in breast cancer survivors (BCS) is still an unmet medical need: results of an Italian Delphi Panel. *Support Care Cancer.* 2020;28(6):2507–2512. doi:10.1007/s00520-019-05272-4
18. The NAMS 2020 GSM Position Statement Editorial Panel. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. *Menopause.* 2020;27(9):976–992. doi:10.1097/GME.0000000000001609
19. Faubion SS, Larkin LC, Stuenkel CA, et al. Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women's Sexual Health. *Menopause.* 2018;25(6):596–608. doi:10.1097/GME.0000000000001121
20. “The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. *Menopause.* 2022;29(7):767–794. doi:10.1097/GME.0000000000002028
21. American College of Obstetricians and Gynecologists' Committee on Clinical Consensus—Gynecology. Treatment of urogenital symptoms in individuals with a history of estrogen-dependent breast cancer: clinical consensus. *Obstet Gynecol.* 2021;138(6):950–960. doi:10.1097/AOG.00000000000004601
22. Carter J, Lacchetti C, Andersen BL, et al. Interventions to address sexual problems in people with cancer: American Society of Clinical Oncology clinical practice guideline adaptation of Cancer Care Ontario guideline. *J Clin Oncol.* 2018;36(5):492–511. doi:10.1200/JCO.2017.75.8995
23. Hillard TC, Nappi RE. The heat is on. *Climacteric.* 2020;23(sup1):S1–S2. doi:10.1080/13697137.2020.1828855
24. Biglia N, Bounous VE, Sgro LG, D'Alonzo M, Pecchio S, Nappi RE. Genitourinary syndrome of menopause in breast cancer survivors: are we facing new and safe hopes? *Clin Breast Cancer.* 2015;15(6):413–420. doi:10.1016/j.clbc.2015.06.005
25. Zerbinati N, Serati M, Orioni M, et al. Microscopic and ultrastructural modifications of postmenopausal atrophic vaginal mucosa after fractional carbon dioxide laser treatment. *Lasers Med Sci.* 2015;30(1):429–436. doi:10.1007/s10103-014-1677-2
26. Hillard TC. Lasers in the era of evidence-based medicine. *Climacteric.* 2020;23(sup1):S6–S10. doi:10.1080/13697137.2020.1774536
27. Adelman M, Nygaard IE. Time for a “Pause” on the use of vaginal laser. *JAMA.* 2021;326(14):1378–1380. doi:10.1001/jama.2021.14809
28. Nappi RE, Murina F, Perrone G, Villa P, Biglia N. Clinical profile of women with vulvar and vaginal atrophy who are not candidates for local vaginal estrogen therapy. *Minerva Ginecol.* 2017;69(4):370–380. doi:10.23736/S0026-4784.17.04064-3
29. Shobeiri SA, Kerkhof MH, Minassian VA, Bazi T; IUGA Research and Development Committee. IUGA committee opinion: laser-based vaginal devices for treatment of stress urinary incontinence, genitourinary syndrome of menopause, and vaginal laxity. *Int Urogynecol J.* 2019;30(3):371–376. doi:10.1007/s00192-018-3830-0
30. Phillips C, Hillard T, Salvatore S, Cardozo L, Toozs-Hobson P; Royal College of Obstetricians and Gynaecologists. Laser treatment for genitourinary syndrome of menopause: scientific impact Paper No. 72 (July 2022). *BJOG.* 2022;129(12):e89–e94. doi:10.1111/1471-0528.17195

31. US Food and Drug Administration [homepage on the Internet]. FDA warns against use of energy-based devices to perform vaginal “rejuvenation” or vaginal cosmetic procedures: FDA safety communication. Available from: <https://www.fda.gov/medical-devices/safety-communications/fdawarns-against-use-energy-based-devices-perform-vaginal-rejuvenation-or-vaginal-cosmetic>. Accessed November 19, 2022.
32. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. 2021;372:n71. doi:10.1136/bmj.n71
33. Pagano T, De Rosa P, Vallone R, et al. Fractional microablative CO<sub>2</sub> laser for vulvovaginal atrophy in women treated with chemotherapy and/or hormonal therapy for breast cancer: a retrospective study. *Menopause*. 2016;23(10):1108–1113. doi:10.1097/GME.0000000000000672
34. Pieralli A, Fallani MG, Becorpi A, et al. Fractional CO<sub>2</sub> laser for vulvovaginal atrophy (VVA) dyspareunia relief in breast cancer survivors. *Arch Gynecol Obstet*. 2016;294(4):841–846. doi:10.1007/s00404-016-4118-6
35. Pagano T, De Rosa P, Vallone R, et al. Fractional microablative CO<sub>2</sub> laser in breast cancer survivors affected by iatrogenic vulvovaginal atrophy after failure of nonestrogenic local treatments: a retrospective study. *Menopause*. 2018;25(6):657–662. doi:10.1097/GME.0000000000001053
36. Becorpi A, Campisciano G, Zanotta N, et al. Fractional CO<sub>2</sub> laser for genitourinary syndrome of menopause in breast cancer survivors: clinical, immunological, and microbiological aspects. *Lasers Med Sci*. 2018;33(5):1047–1054. doi:10.1007/s10103-018-2471-3
37. Pearson A, Booker A, Tio M, Marx G. Vaginal CO<sub>2</sub> laser for the treatment of vulvovaginal atrophy in women with breast cancer: LAAVA pilot study. *Breast Cancer Res Treat*. 2019;178(1):135–140. doi:10.1007/s10549-019-05384-9
38. Gittens P, Mullen G. The effects of fractional microablative CO<sub>2</sub> laser therapy on sexual function in postmenopausal women and women with a history of breast cancer treated with endocrine therapy. *J Cosmet Laser Ther*. 2019;21(3):127–131. doi:10.1080/14764172.2018.1481510
39. Angioli R, Stefano S, Filippini M, et al. Effectiveness of CO<sub>2</sub> laser on urogenital syndrome in women with a previous gynecological neoplasia: a multicentric study. *Int J Gynecol Cancer*. 2020;30(5):590–595. doi:10.1136/ijgc-2019-001028
40. Hersant B, Werkoff G, Sawan D, et al. Carbon dioxide laser treatment for vulvovaginal atrophy in women treated for breast cancer: preliminary results of the feasibility EPIONE trial. *Ann Chir Plast Esthet*. 2020;65(4):e23–e31. doi:10.1016/j.anplas.2020.05.002
41. Quick AM, Zvinovski F, Hudson C, et al. Fractional CO<sub>2</sub> laser therapy for genitourinary syndrome of menopause for breast cancer survivors. *Support Care Cancer*. 2020;28(8):3669–3677. doi:10.1007/s00520-019-05211-3
42. Veron L, Wehrer D, Annerose-Zéphir G, et al. Effects of local laser treatment on vulvovaginal atrophy among women with breast cancer: a prospective study with long-term follow-up. *Breast Cancer Res Treat*. 2021;188(2):501–509. doi:10.1007/s10549-021-06226-3
43. Siliquini GP, Bouounis VE, Novara L, Giorgi M, Bert F, Biglia N. Fractional CO<sub>2</sub> vaginal laser for the genitourinary syndrome of menopause in breast cancer survivors. *Breast J*. 2021;27(5):448–455. doi:10.1111/tbj.14211
44. Salvatore S, Nappi RE, Casiraghi A, et al. Microablative fractional CO<sub>2</sub> laser for vulvovaginal atrophy in women with a history of breast cancer: a pilot study at 4-week follow-up. *Clin Breast Cancer*. 2021;21(5):e539–e546. doi:10.1016/j.clbc.2021.01.006
45. Quick AM, Zvinovski F, Hudson C, et al. Patient-reported sexual function of breast cancer survivors with genitourinary syndrome of menopause after fractional CO<sub>2</sub> laser therapy. *Menopause*. 2021;28(6):642–649. doi:10.1097/GME.0000000000001738
46. Gardner AN, Aschkenazi SO. The short-term efficacy and safety of fractional CO<sub>2</sub> laser therapy for vulvovaginal symptoms in menopause, breast cancer, and lichen sclerosus. *Menopause*. 2021;28(5):511–516. doi:10.1097/GME.0000000000001727
47. Quick AM, Hundley A, Evans C, et al. Long-term follow-up of fractional CO<sub>2</sub> laser therapy for genitourinary syndrome of menopause in breast cancer survivors. *J Clin Med*. 2022;11(3):774. doi:10.3390/jcm11030774
48. Mension E, Alonso I, Anglès-Acedo S, et al. Effect of fractional carbon dioxide vs sham laser on sexual function in survivors of breast cancer receiving aromatase inhibitors for genitourinary syndrome of menopause: the LIGHT randomized clinical trial. *JAMA Netw Open*. 2023;6(2):e2255697. doi:10.1001/jamanetworkopen.2022.55697
49. Gambacciani M, Levancini M. Vaginal erbium laser as second-generation thermotherapy for the genitourinary syndrome of menopause: a pilot study in breast cancer survivors. *Menopause*. 2017;24(3):316–319. doi:10.1097/GME.0000000000000761
50. Mothes AR, Runnebaum M, Runnebaum IB. Ablative dual-phase Erbium:YAG laser treatment of atrophy-related vaginal symptoms in postmenopausal breast cancer survivors omitting hormonal treatment. *J Cancer Res Clin Oncol*. 2018;144(5):955–960. doi:10.1007/s00432-018-2614-8
51. Arêas F, Valadares ALR, Conde DM, Costa-Paiva L. The effect of vaginal erbium laser treatment on sexual function and vaginal health in women with a history of breast cancer and symptoms of the genitourinary syndrome of menopause: a prospective study. *Menopause*. 2019;26(9):1052–1058. doi:10.1097/GME.0000000000001353
52. Gold D, Nicolay L, Avian A, et al. Vaginal laser therapy versus hyaluronic acid suppositories for women with symptoms of urogenital atrophy after treatment for breast cancer: a randomized controlled trial. *Maturitas*. 2022;167:1–7. doi:10.1016/j.maturitas.2022.08.013
53. Gordon C, Gonzales S, Krychman ML. Rethinking the techno vagina: a case series of patient complications following vaginal laser treatment for atrophy. *Menopause*. 2019;26(4):423–427. doi:10.1097/GME.0000000000001293
54. Knight C, Logan V, Fenlon D. A systematic review of laser therapy for vulvovaginal atrophy/genitourinary syndrome of menopause in breast cancer survivors. *Ecancermedicalscience*. 2019;13:988. doi:10.3332/ecancer.2019.988
55. Jha S, Wyld L, Krishnaswamy PH. The impact of vaginal laser treatment for genitourinary syndrome of menopause in breast cancer survivors: a systematic review and meta-analysis. *Clin Breast Cancer*. 2019;19(4):e556–e562. doi:10.1016/j.clbc.2019.04.007
56. D’Oria O, Giannini A, Buzzaccarini G, et al. Fractional CO<sub>2</sub> laser for vulvo-vaginal atrophy in gynecologic cancer patients: a valid therapeutic choice? A systematic review. *Eur J Obstet Gynecol Reprod Biol*. 2022;277:84–89. doi:10.1016/j.ejogrb.2022.08.012
57. Jugulytė N, Žukienė G, Bartkevičienė D. Emerging use of vaginal laser to treat genitourinary syndrome of menopause for breast cancer survivors: a review. *Medicina*. 2023;59:132. doi:10.3390/medicina59010132
58. Athanasiou S, Pitsouni E, Douskos A, Salvatore S, Loutradis D, Grigoriadis T. Intravaginal energy-based devices and sexual health of female cancer survivors: a systematic review and meta-analysis. *Lasers Med Sci*. 2020;35(1):1–11. doi:10.1007/s10103-019-02855-9
59. Filippini M, Porcari I, Ruffolo AF, et al. CO<sub>2</sub>-laser therapy and genitourinary syndrome of menopause: a systematic review and meta-analysis. *J Sex Med*. 2022;19(3):452–470. doi:10.1016/j.jsxm.2021.12.010
60. Liu M, Li F, Zhou Y, Cao Y, Li S, Li Q. Efficacy of CO<sub>2</sub> laser treatment in postmenopausal women with vulvovaginal atrophy: a meta-analysis. *Int J Gynaecol Obstet*. 2022;158(2):241–251. doi:10.1002/ijgo.13973
61. Mension E, Alonso I, Tortajada M, et al. Vaginal laser therapy for genitourinary syndrome of menopause - systematic review. *Maturitas*. 2022;156:37–59. doi:10.1016/j.maturitas.2021.06.005

62. Khamis Y, Abdelhakim AM, Labib K, et al. Vaginal CO<sub>2</sub> laser therapy versus sham for genitourinary syndrome of menopause management: a systematic review and meta-analysis of randomized controlled trials. *Menopause*. 2021;28(11):1316–1322. doi:10.1097/GME.0000000000001845
63. Quick AM, Dockter T, Le-Rademacher J, et al. Pilot study of fractional CO<sub>2</sub> laser therapy for genitourinary syndrome of menopause in gynecologic cancer survivors. *Maturitas*. 2021;144:37–44. doi:10.1016/j.maturitas.2020.10.018
64. Cruff J, Khandwala S. A double-blind randomized sham-controlled trial to evaluate the efficacy of fractional carbon dioxide laser therapy on genitourinary syndrome of menopause. *J Sex Med*. 2021;18(4):761–769. doi:10.1016/j.jsxm.2021.01.188
65. Li FG, Maheux-Lacroix S, Deans R, et al. Effect of fractional carbon dioxide laser vs sham treatment on symptom severity in women with postmenopausal vaginal symptoms: a randomized clinical trial. *JAMA*. 2021;326(14):1381–1389. doi:10.1001/jama.2021.14892
66. Page AS, Verbakel JY, Verhaeghe J, Latul YP, Housmans S, Deprest J. Laser versus sham for genitourinary syndrome of menopause: a randomised controlled trial. *BJOG*. 2022. doi:10.1111/1471-0528.17335
67. Mortensen OE, Christensen SE, Løkkegaard E. The evidence behind the use of LASER for genitourinary syndrome of menopause, vulvovaginal atrophy, urinary incontinence and lichen sclerosus: a state-of-the-art review. *Acta Obstet Gynecol Scand*. 2022;101(6):657–692. doi:10.1111/aogs.14353
68. Pérez-López FR, Varikasuvu SR. Vulvovaginal atrophy management with a laser: the placebo effect or the conditioning Pavlov reflex. *Climacteric*. 2022;25(4):323–326. doi:10.1080/13697137.2022.2050207
69. Mackova K, Mazzer AM, Mori Da Cunha M, et al. Vaginal Er:YAG laser application in the menopausal ewe model: a randomised estrogen and sham-controlled trial. *BJOG*. 2021;128(6):1087–1096. doi:10.1111/1471-0528.16558
70. Tadir Y, Gaspar A, Lev-Sagie A, et al. Light and energy based therapeutics for genitourinary syndrome of menopause: consensus and controversies. *Lasers Surg Med*. 2017;49(2):137–159. doi:10.1002/lsm.22637
71. Dutra PFSP, Heinke T, Pinho SC, et al. Comparison of topical fractional CO<sub>2</sub> laser and vaginal estrogen for the treatment of genitourinary syndrome in postmenopausal women: a randomized controlled trial. *Menopause*. 2021;28(7):756–763. doi:10.1097/GME.0000000000001797
72. Gaspar A, Silva J, Calderon A, Di Placido V, Vizintin Z. Histological findings after non-ablative Er:YAG laser therapy in women with severe vaginal atrophy. *Climacteric*. 2020;23(sup1):S11–S13. doi:10.1080/13697137.2020.1764525
73. Perino A, Calligaro A, Forlani F, et al. Vulvo-vaginal atrophy: a new treatment modality using thermo-ablative fractional CO<sub>2</sub> laser. *Maturitas*. 2015;80(3):296–301. doi:10.1016/j.maturitas.2014.12.006
74. Lang P, Dell JR, Rosen L, Weiss P, Karram M. Fractional CO<sub>2</sub> laser of the vagina for genitourinary syndrome of menopause: is the out-of-pocket cost worth the outcome of treatment? *Lasers Surg Med*. 2017;49(10):882–885. doi:10.1002/lsm.22713
75. Di Donato V, O D, Scudo M, et al. Safety evaluation of fractional CO<sub>2</sub> laser treatment in post-menopausal women with vaginal atrophy: a prospective observational study. *Maturitas*. 2020;135:34–39. doi:10.1016/j.maturitas.2020.02.009
76. Preti M, Vieira-Baptista P, Digesu GA, et al. The clinical role of LASER for vulvar and vaginal treatments in gynecology and female urology: an ICS/ISSVD best practice consensus document. *Neurourol Urodyn*. 2019;38(3):1009–1023. doi:10.1002/nau.23931
77. Cucinella L, Martini E, Tiranini L, et al. Genitourinary syndrome of menopause: should we treat symptoms or signs? *Curr Opin Endocr Metab Res*. 2022;22:100386. doi:10.1016/j.coemr.2022.100386
78. Castelo-Branco C, Mension E. Are we assessing genitourinary syndrome of menopause properly? *Climacteric*. 2021;24(6):529–530. doi:10.1080/13697137.2021.1945573
79. Phillips NA, Bachmann GA. The genitourinary syndrome of menopause. *Menopause*. 2021;28(5):579–588. doi:10.1097/GME.0000000000001728
80. Balica AC, Cooper AM, McKeivitt MK, et al. Dyspareunia Related to GSM: association of Total Vaginal Thickness via Transabdominal Ultrasound. *J Sex Med*. 2019;16(12):2038–2042. doi:10.1016/j.jsxm.2019.08.019
81. Peker H, Gursoy A. Relationship between genitourinary syndrome of menopause and 3D high-frequency endovaginal ultrasound measurement of vaginal wall thickness. *J Sex Med*. 2021;18(7):1230–1235. doi:10.1016/j.jsxm.2021.05.004
82. Athanasiou S, Pitsouni E, Antonopoulou S, et al. The effect of microablative fractional CO<sub>2</sub> laser on vaginal flora of postmenopausal women. *Climacteric*. 2016;19(5):512–518. doi:10.1080/13697137.2016.1212006
83. Sipos AG, Pákozdy K, Jäger S, Larson K, Takacs P, Kozma B. Fractional CO<sub>2</sub> laser treatment effect on cervicovaginal lavage zinc and copper levels: a prospective cohort study. *BMC Womens Health*. 2021;21(1):235. doi:10.1186/s12905-021-01379-1
84. Lensen S, Bell RJ, Carpenter JS, et al. A core outcome set for genitourinary symptoms associated with menopause: the COMMA (Core Outcomes in Menopause) global initiative. *Menopause*. 2021;28(8):859–866. doi:10.1097/GME.0000000000001788
85. Palacios S, Nappi RE, Bruyniks N, Particco M, Panay N; EVES Study Investigators. The European Vulvovaginal Epidemiological Survey (EVES): prevalence, symptoms and impact of vulvovaginal atrophy of menopause. *Climacteric*. 2018;21(3):286–291. doi:10.1080/13697137.2018.1446930
86. Nappi RE, Palacios S, Bruyniks N, Particco M, Panay N; EVES Study investigators. The burden of vulvovaginal atrophy on women's daily living: implications on quality of life from a face-to-face real-life survey. *Menopause*. 2019;26(5):485–491. doi:10.1097/GME.0000000000001260
87. Particco M, Djumaeva S, Nappi RE, Panay N, Palacios S; EVES Study investigators. The European Vulvovaginal Epidemiological Survey (EVES): impact on sexual function of vulvovaginal atrophy of menopause. *Menopause*. 2020;27(4):423–429. doi:10.1097/GME.0000000000001496
88. Panay N, Palacios S, Bruyniks N, Particco M, Nappi RE; EVES Study investigators. Symptom severity and quality of life in the management of vulvovaginal atrophy in postmenopausal women. *Maturitas*. 2019;124:55–61. doi:10.1016/j.maturitas.2019.03.013
89. Flynn KE, Lin L, Carter J, et al. Correspondence between clinician ratings of vulvovaginal health and patient-reported sexual function after cancer. *J Sex Med*. 2021;18(10):1768–1774. doi:10.1016/j.jsxm.2021.07.011
90. Kieseker GA, Anderson DJ, Porter-Steele J, McCarthy AL. A psychometric evaluation of the Female Sexual Function Index in women treated for breast cancer. *Cancer Med*. 2022;11(6):1511–1523. doi:10.1002/cam4.4516
91. Nappi RE. New attitudes to sexuality in the menopause: clinical evaluation and diagnosis. *Climacteric*. 2007;10(Suppl 2):105–108. doi:10.1080/13697130701599876
92. Mension E, Alonso I, Castelo-Branco C. Genitourinary syndrome of menopause: current treatment options in breast cancer survivors - systematic review. *Maturitas*. 2021;143:47–58. doi:10.1016/j.maturitas.2020.08.010
93. Vegunta S, Kuhle CL, Vencill JA, Lucas PH, Mussallem DM. Sexual health after a breast cancer diagnosis: addressing a forgotten aspect of survivorship. *J Clin Med*. 2022;11(22):6723. doi:10.3390/jcm11226723

94. Tounkel I, Nalubola S, Schulz A, Lakhi N. Sexual health screening for gynecologic and breast cancer survivors: a review and critical analysis of validated screening tools. *Sex Med.* 2022;10(2):100498. doi:10.1016/j.esxm.2022.100498
95. Mlakar I, Lin S, Nateqi J, et al. Establishing an expert consensus on key indicators of the quality of life among breast cancer survivors: a modified delphi study. *J Clin Med.* 2022;11(7):2041. doi:10.3390/jcm11072041
96. Hickey M, Emery LI, Gregson J, Doherty DA, Saunders CM. The multidisciplinary management of menopausal symptoms after breast cancer: a unique model of care. *Menopause.* 2010;17(4):727–733. doi:10.1097/gme.0b013e3181d672f6
97. Lubían López DM. Management of genitourinary syndrome of menopause in breast cancer survivors: an update. *World J Clin Oncol.* 2022;13(2):71–100. doi:10.5306/wjco.v13.i2.71
98. Faubion SS, Kingsberg SA. Understanding the unmet sexual health needs of women with breast cancer. *Menopause.* 2019;26(8):811–813. doi:10.1097/GME.0000000000001372
99. Vizza R, Capomolla EM, Tosetto L, et al. Sexual dysfunctions in breast cancer patients: evidence in context. *Sex Med Rev.* 2023; qead006. doi:10.1093/sxmrev/qead006
100. Nappi RE, Martella S, Albani F, Cassani C, Martini E, Landoni F. Hyaluronic acid: a valid therapeutic option for early management of genitourinary syndrome of menopause in cancer survivors? *Healthcare.* 2022;10(8):1528. doi:10.3390/healthcare10081528
101. Garzon S, Apostolopoulos V, Stojanovska L, Ferrari F, Mathyk BA, Laganà AS. Non-oestrogenic modalities to reverse urogenital aging. *Prz Menopauzalny.* 2021;20(3):140–147. doi:10.5114/pm.2021.109772
102. Jang YC, Leung CY, Huang HL. Comparison of severity of genitourinary syndrome of menopause symptoms after carbon dioxide laser vs vaginal estrogen therapy: a systematic review and meta-analysis. *JAMA Netw Open.* 2022;5(9):e2232563. doi:10.1001/jamanetworkopen.2022.32563
103. Mension E, Alonso I, Cebrecos I, et al. Safety of prasterone in breast cancer survivors treated with aromatase inhibitors: the VIBRA pilot study. *Climacteric.* 2022;25(5):476–482. doi:10.1080/13697137.2022.2050208
104. Cai B, Simon J, Villa P, et al. No increase in incidence or risk of recurrence of breast cancer in ospemifene-treated patients with vulvovaginal atrophy (VVA). *Maturitas.* 2020;142:38–44. doi:10.1016/j.maturitas.2020.06.021
105. Nappi RE, Cucinella L, Martini E, Cassani C. The role of hormone therapy in urogenital health after menopause. *Best Pract Res Clin Endocrinol Metab.* 2021;35(6):101595. doi:10.1016/j.beem.2021.101595
106. Salvatore S, Benini V, Ruffolo AF, et al. Current challenges in the pharmacological management of genitourinary syndrome of menopause. *Expert Opin Pharmacother.* 2022. doi:10.1080/14656566.2022.2152326
107. Simon JA, Davis SR, Althof SE, et al. Sexual well-being after menopause: an International Menopause Society White Paper. *Climacteric.* 2018;21(5):415–427. doi:10.1080/13697137.2018.1482647
108. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. *CA Cancer J Clin.* 2022;72(1):7–33. doi:10.3322/caac.21708
109. Mili N, Paschou SA, Armeni A, Georgopoulos N, Goulis DG, Lambrinouadaki I. Genitourinary syndrome of menopause: a systematic review on prevalence and treatment. *Menopause.* 2021;28(6):706–716. doi:10.1097/GME.0000000000001752
110. Tranoulis A, Georgiou D, Michala L. Laser treatment for the management of genitourinary syndrome of menopause after breast cancer. Hope or hype? *Int Urogynecol J.* 2019;30(11):1879–1886. doi:10.1007/s00192-019-04051-3

International Journal of Women's Health

Dovepress

Publish your work in this journal

The International Journal of Women's Health is an international, peer-reviewed open-access journal publishing original research, reports, editorials, reviews and commentaries on all aspects of women's healthcare including gynecology, obstetrics, and breast cancer. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/international-journal-of-womens-health-journal>